New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
13:55 EDTPRGOPerrigo weakness creates buying opportunity, says Argus
After Perrigo reported lower than expected Q3 EPS and reduced its guidance, Argus reports that the company's valuation are now in the lower portion of their historical levels. The firm cut its price target on the shares to $160 from $175 but it thinks the company has a number of positive catalysts and keeps a Buy rating.
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
08:08 EDTPRGOGalmed and Perrigo sign agreement for aramchol API production
Galmed (GLMD) has entered into a Manufacturing Services Agreement with Perrigo (PRGO) subsidiary Perrigo API Ltd. for the large-scale production of the active pharmaceutical ingredient of Galmed's product candidate, aramchol. The API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed's potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH. The agreement also provides Perrigo with the option to manufacture commercial supplies of the aramchol API in the future.
January 20, 2015
11:16 EDTPRGOPerrigo management to meet with B. Riley
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use